Politico December 8, 2023
Carmen Paun, Erin Schumaker, Evan Peng, Daniel Payne and Ruth Reader

Pharmaceutical companies and medical device manufacturers expect artificial intelligence to have a profound impact on their businesses next year and are already experimenting with it, according to a Deloitte Center for Health Solutions survey of some 120 executives.

Drug and device makers are exploring how advanced AI could automate repetitive functions, reimagine supply chains and support compliance and regulatory affairs, according to Deloitte.

Who’s in charge? About a quarter of the pharma executives responding to the survey said they have established governance and oversight for AI and another half said they were expecting to do it over the next year.

Medical device manufacturers are slightly behind: One in 5 respondents from the industry said they have a governance and oversight...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Medical Devices, Pharma, Pharma / Biotech, Technology
How Americans feel about weight-loss drugs, in 3 charts
Drugmakers prep for bird flu outbreak, despite continued low risk
Heart health differences in men and women: Tiny RNA molecules play key role, study finds
Advancing Cancer Care: The Role of Radiopharmaceuticals in Precision Medicine
STAT+: Nobel laureates call on National Academies and biotech CEOs to speak out against Trump attacks on science

Share This Article